What were Neuland Laboratories Ltd's latest quarterly results?
Neuland Laboratories Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -59.8% (stable)
- Revenue Growth YoY: +10.6%
- Operating Margin: 18.0% (volatile)
Neuland Laboratories Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +36.9%WeakNew This Week
In , Neuland Laboratories Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +36.9% relative strength. Fundamentals: Weak.
Neuland Laboratories Ltd Key Facts
- PE Ratio
- 127.0x
- Market Cap
- ₹22,665 Cr
- PAT Growth YoY
- -60%
- Revenue Growth YoY
- +11%
- OPM
- 18.0%
- RS vs Nifty 500
- +36.9%
PE: At PeakDanger Bubble
What's Happening
⚠️PE rising despite falling earnings — price running ahead of reality
📊Debt increased 69% YoY — leverage rising
🌐FII stake decreased 5.9% this quarter
🏛️DII accumulation — stake up 7.2%
Key Numbers
PAT Growth YoY
-60%
Stable
Revenue YoY
+11%
Inflection Up
Operating Margin
18.0%
-400 bps YoY
PE Ratio
127.0
Current Price
₹17,666
Dividend Yield
0.07%
Fundamental Score
30/100
Weak
3Y PAT CAGR
+60%
Market Cap
22.7K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Neuland Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +11% | +16% | Inflection Up |
| PAT (Net Profit) | -60% | +60% | Stable |
| OPM | 18.0% | -400 bps | Volatile |
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Neuland Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Neuland Laboratories Ltd's profit growing or declining?
Neuland Laboratories Ltd's profit is declining with an stable trend.
- PAT Growth YoY: -59.8% (latest quarter)
- PAT Growth QoQ: -57.7% (sequential)
- 3-Year PAT CAGR: +59.6%
- Trend: Stable — consistent growth pattern
What is Neuland Laboratories Ltd's revenue growth trend?
Neuland Laboratories Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +10.6%
- Revenue Growth QoQ: -14.4% (sequential)
- 3-Year Revenue CAGR: +15.8%
How is Neuland Laboratories Ltd's operating margin trending?
Neuland Laboratories Ltd's operating margin is volatile.
- Current OPM: 18.0%
- OPM Change YoY: -4.0% basis points
- OPM Change QoQ: -12.0% basis points
What is Neuland Laboratories Ltd's 3-year profit and revenue CAGR?
Neuland Laboratories Ltd's long-term compounding rates
- 3-Year Profit CAGR: +59.6%
- 3-Year Revenue CAGR: +15.8%
Is Neuland Laboratories Ltd's growth accelerating or decelerating?
Neuland Laboratories Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -159.8% bps
- Sequential Acceleration: -100.0% bps
- Margin Warning: Operating margins are under pressure
What is Neuland Laboratories Ltd's trailing twelve month (TTM) performance?
Neuland Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹180 Cr
- TTM PAT Growth: -40.2% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +2.7% YoY
- TTM Operating Margin: 20.4%
What is Neuland Laboratories Ltd's current PE ratio?
Neuland Laboratories Ltd's current PE ratio is 127.0x.
- Current PE: 127.0x
- Market Cap: 22.7K Cr
- Dividend Yield: 0.07%
What is Neuland Laboratories Ltd's price-to-book ratio?
Neuland Laboratories Ltd's price-to-book ratio is 14.0x.
- Price-to-Book (P/B): 14.0x
- Book Value per Share: ₹1263
- Current Price: ₹17666
Is Neuland Laboratories Ltd a fundamentally strong company?
Neuland Laboratories Ltd is rated Weak with a fundamental score of 30.27/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +10.6% (10% weight)
- PAT Growth YoY: -59.8% (10% weight)
- PAT Growth QoQ: -57.7% (10% weight)
- Margins stable (10% weight)
Is Neuland Laboratories Ltd debt free?
Neuland Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹265 Cr
What is Neuland Laboratories Ltd's return on equity (ROE) and ROCE?
Neuland Laboratories Ltd's return ratios over recent years
- FY2023: ROCE 21.0%
- FY2024: ROCE 33.0%
- FY2025: ROCE 19.0%
Is Neuland Laboratories Ltd's cash flow positive?
Neuland Laboratories Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹317 Cr
- Free Cash Flow (FCF): ₹19 Cr
- CFO/PAT Ratio: 122% (strong cash conversion)
What is Neuland Laboratories Ltd's dividend yield?
Neuland Laboratories Ltd's current dividend yield is 0.07%.
- Dividend Yield: 0.07%
- Current Price: ₹17666
Who holds Neuland Laboratories Ltd shares — promoters, FII, DII?
Neuland Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 32.6%
- FII (Foreign): 20.5%
- DII (Domestic): 15.8%
- Public: 31.1%
Is promoter holding increasing or decreasing in Neuland Laboratories Ltd?
Neuland Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 32.6% (Mar 2026)
- Previous Quarter: 32.6% (Dec 2025)
- Change: 0.00% (stable)
How long has Neuland Laboratories Ltd been outperforming Nifty 500?
Neuland Laboratories Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Neuland Laboratories Ltd a new momentum entry or an established outperformer?
Neuland Laboratories Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Neuland Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Neuland Laboratories Ltd may be worth studying
- Cash flow is positive — CFO ₹317 Cr
What is the investment thesis for Neuland Laboratories Ltd?
Neuland Laboratories Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +10.6% YoY
Risk Factors (Bear Case)
- Margins under pressure
What is the future outlook for Neuland Laboratories Ltd?
Neuland Laboratories Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: turning around (inflection up)
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.